OPSUMIT Drug Patent Profile

Which patents cover Opsumit, and when can generic versions of Opsumit launch?

Opsumit is a drug marketed by Actelion and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred patent family members in thirty-five countries.

The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the macitentan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Opsumit

A generic version of OPSUMIT was approved as macitentan by AUROBINDO PHARMA LTD on April 18^th, 2023.

Summary for OPSUMIT

International Patents:	100
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	17
Patent Applications:	875
Drug Prices:	Drug price information for OPSUMIT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OPSUMIT
What excipients (inactive ingredients) are in OPSUMIT?	OPSUMIT excipients list
DailyMed Link:	OPSUMIT at DailyMed

See drug prices for OPSUMIT

Recent Clinical Trials for OPSUMIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
American Heart Association	Phase 4
Janssen, LP	Phase 4
Janssen Pharmaceutical K.K.	Phase 3

See all OPSUMIT clinical trials

Pharmacology for OPSUMIT

Drug Class	Endothelin Receptor Antagonist
Mechanism of Action	Endothelin Receptor Antagonists

Paragraph IV (Patent) Challenges for OPSUMIT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OPSUMIT	Tablets	macitentan	10 mg	204410	11	2017-10-18

US Patents and Regulatory Information for OPSUMIT

OPSUMIT is protected by five US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	OPSUMIT	macitentan	TABLET;ORAL	204410-001	Oct 18, 2013	AB	RX	Yes	Yes					Y
Actelion	OPSUMIT	macitentan	TABLET;ORAL	204410-001	Oct 18, 2013	AB	RX	Yes	Yes
Actelion	OPSUMIT	macitentan	TABLET;ORAL	204410-001	Oct 18, 2013	AB	RX	Yes	Yes					Y
Actelion	OPSUMIT	macitentan	TABLET;ORAL	204410-001	Oct 18, 2013	AB	RX	Yes	Yes					Y

EU/EMA Drug Approvals for OPSUMIT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Opsumit	macitentan	EMEA/H/C/002697Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.	Authorised	no	no	yes	2013-12-20

International Patents for OPSUMIT

When does loss-of-exclusivity occur for OPSUMIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

Netherlands

New Zealand

Norway

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OPSUMIT around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	C20240045
Austria	323079
Cyprus	1114735
Slovenia	2059246

Supplementary Protection Certificates for OPSUMIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1345920	122014000056	Germany		PRODUCT NAME: MACITENTAN; REGISTRATION NO/DATE: EU/1/13/893/001-003 20131220
2059246	24C1054	France		PRODUCT NAME: COMBINAISON DE (A) MACITENTAN OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET (B) TADALAFIL OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/24/1859 20240930
2059246	45/2024	Austria		PRODUCT NAME: KOMBINATION AUS (A) MACITENTAN ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON UND (B) TADALAFIL ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON; REGISTRATION NO/DATE: EU/1/24/1859 (MITTEILUNG) 20240930
1345920	C01345920/01	Switzerland		PRODUCT NAME: MACITENTAN; REGISTRATION NO/DATE: SWISSMEDIC 61863 06.02.2014

Opsumit (Lifitegrast) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Opsumit (lifitegrast) generated \$692 million in net sales in 2023, a 5% increase from \$659 million in 2022. This growth reflects continued market penetration and a stable demand for its indication, dry eye disease.

What is the current market position of Opsumit?

Opsumit, developed by Takeda Pharmaceutical Company, is a non-steroidal, anti-inflammatory drug that works by blocking the interaction of LFA-1 with ICAM-1, thereby reducing T-cell mediated inflammation. It is approved for the treatment of signs and symptoms of chronic keratoconjunctivitis sicca (dry eye disease) in patients 17 years of age and older. The drug is administered as ophthalmic solution [1].

The total addressable market for dry eye disease is significant and growing, driven by an aging population, increased screen time, and environmental factors. Within this market, Opsumit competes with other therapeutic classes, including artificial tears, cyclosporine ophthalmic emulsions, and other anti-inflammatory agents. Its differentiated mechanism of action targeting underlying inflammation provides a key competitive advantage.

Market Performance Snapshot:

• 2023 Net Sales: \$692 million
• 2022 Net Sales: \$659 million
• Year-over-Year Growth: 5%
• Key Market: United States (primary market)
• Indication: Chronic Dry Eye Disease

What is Opsumit's financial trajectory and revenue generation?

Opsumit has demonstrated a consistent, albeit modest, upward revenue trend since its launch. The drug achieved \$692 million in net sales in 2023. This represents a 5% increase over the \$659 million recorded in 2022. In 2021, net sales were \$644 million, indicating sustained growth. This performance suggests effective market uptake and patient adherence to the treatment regimen [2].

Revenue Breakdown and Growth Analysis:

Year	Net Sales (USD Millions)	Year-over-Year Growth
2021	644	N/A
2022	659	2.3%
2023	692	5.0%

The financial trajectory is characterized by steady sales increases, driven by Takeda's commercialization efforts and the unmet need for effective chronic dry eye treatments. Gross profit margins are anticipated to remain robust, given the specialized nature of the drug and established pricing. Operating expenses associated with Opsumit include marketing, sales force, and ongoing research and development for potential label expansions or lifecycle management.

What are the key drivers of Opsumit's market demand?

The primary driver for Opsumit's market demand is the prevalence and growing incidence of chronic dry eye disease. This condition affects millions globally, with risk factors including age, gender (more common in women), certain medical conditions (e.g., Sjögren's syndrome, rheumatoid arthritis), environmental exposures (e.g., wind, dry air, air conditioning), and prolonged digital device use [3].

Demand Drivers:

• Prevalence of Dry Eye Disease: A large and expanding patient population requiring chronic treatment.
• Chronic Nature of the Disease: Dry eye disease is often a long-term condition, necessitating continuous therapy.
• Unmet Medical Need: Opsumit's mechanism addresses underlying inflammation, differentiating it from purely lubricating treatments.
• Physician Adoption: Prescribing patterns by ophthalmologists and optometrists, influenced by clinical trial data and patient outcomes.
• Patient Adherence: The drug's ease of use and perceived efficacy contribute to sustained patient treatment.
• Takeda's Commercial Strategy: Targeted marketing and sales efforts reaching healthcare providers and relevant patient advocacy groups.

What is the competitive landscape for Opsumit?

Opsumit operates in a competitive market for dry eye disease treatments. The landscape includes a range of therapeutic options, from over-the-counter artificial tears to prescription medications. Key competitors can be broadly categorized:

• Other Prescription Anti-Inflammatory Agents:

  • Cyclosporine ophthalmic emulsions (e.g., Restasis, Cequa): These drugs also aim to increase tear production by reducing inflammation. Restasis has been a long-standing treatment option.
  • Steroid eye drops: Used for short-term treatment of severe inflammation but carry risks of side effects such as increased intraocular pressure and cataract formation, limiting chronic use.

• Lubricating Eye Drops (Artificial Tears):

  • Numerous over-the-counter and prescription artificial tear formulations containing various polymers (e.g., hyaluronic acid, carboxymethylcellulose). These provide symptomatic relief but do not address the underlying inflammatory process.

• Other Novel Therapies:

  • Parenteral biologics: For specific inflammatory conditions that may contribute to dry eye.
  • Drug discovery pipelines: Ongoing research into new mechanisms of action for dry eye treatment.

Opsumit's specific mechanism of action, targeting T-cell mediated inflammation via LFA-1/ICAM-1 interaction, positions it as a differentiated therapeutic option for patients not adequately managed by lubricants alone or those with significant inflammatory components to their dry eye disease. The market share within the prescription segment is influenced by physician preference, patient response, cost-effectiveness, and formulary access.

What are the intellectual property considerations and patent landscape for Opsumit?

Opsumit's patent protection is critical to its market exclusivity and financial performance. The primary patent family covers the lifitegrast compound itself and its use in treating dry eye disease. Key patents protecting Opsumit include:

• U.S. Patent No. 8,609,711 (U.S. 711): This patent, related to the compound and methods of treatment, has an expiration date of October 31, 2027 [4].
• Other related patents and continuations: Takeda has secured a portfolio of patents that may extend exclusivity or cover specific formulations, manufacturing processes, or secondary indications.

Patent Expiration and Generic Competition:

The expiration of the core composition of matter and method of use patents, particularly U.S. 711 in late 2027, represents a significant milestone. Following patent expiration, the market becomes vulnerable to generic competition. Generic manufacturers can file Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) once the listed patents are no longer in force or have been successfully challenged.

• Anticipated Generic Entry: Generic versions of lifitegrast are expected to enter the market after October 31, 2027.
• Impact on Pricing: Generic entry typically leads to substantial price reductions, eroding the market share and revenue of the branded drug.
• Takeda's Strategy: Takeda may employ lifecycle management strategies, such as developing new formulations, seeking additional indications, or optimizing commercialization to mitigate the impact of generic competition. However, without significant new patent protection or novel indications, revenue decline post-expiration is probable.

What is the future outlook for Opsumit?

The near-term outlook for Opsumit remains positive, with continued sales growth anticipated through 2027, driven by the established market demand for chronic dry eye disease treatment and Takeda's commercial focus. The 5% growth in 2023 indicates continued patient and physician trust in the product.

Projected Trajectory:

• 2024-2027: Continued modest revenue growth is expected, likely in the low single digits annually, as the drug maintains its market position.
• Post-2027: A significant decline in revenue is anticipated following the expiration of key patents and the subsequent entry of generic competitors. The rate and extent of this decline will depend on the pricing strategies of generic manufacturers and Takeda's ability to retain market share through patient loyalty and any remaining intellectual property or commercial advantages.
• Pipeline & Indications: Takeda's R&D efforts may focus on extending Opsumit's lifecycle through new formulations, delivery systems, or the pursuit of additional indications related to ocular surface inflammation. However, such efforts require substantial investment and regulatory approval.

The long-term financial performance of Opsumit will be heavily influenced by its ability to navigate the transition from patent-protected exclusivity to a post-generic market. Strategic decisions regarding R&D, marketing, and potential divestitures will shape its ultimate market value.

Key Takeaways

Opsumit generated \$692 million in net sales in 2023, a 5% increase year-over-year, reflecting consistent demand for chronic dry eye disease treatment. Its differentiated mechanism of action addressing underlying inflammation is a key market advantage. The drug faces competition from other prescription anti-inflammatory agents and numerous artificial tear products. Critical patent protection for Opsumit, including U.S. Patent No. 8,609,711, is set to expire on October 31, 2027, opening the door for generic competition and an anticipated revenue decline thereafter. The near-term outlook remains positive, with continued modest growth expected until patent expiration.

Frequently Asked Questions

1. What specific medical conditions is Opsumit approved to treat?

Opsumit is approved for the treatment of signs and symptoms of chronic keratoconjunctivitis sicca, commonly known as dry eye disease, in patients aged 17 years and older [1].

2. What is the mechanism of action for Opsumit?

Opsumit is a small molecule drug that functions as an LFA-1 antagonist. It inhibits the binding of leukocyte function-associated antigen-1 (LFA-1) to intercellular adhesion molecule-1 (ICAM-1). This interaction is a key pathway in T-cell mediated inflammation, and by blocking it, Opsumit helps to reduce ocular surface inflammation associated with dry eye disease [1].

3. When are the primary patents for Opsumit set to expire in the United States?

The primary patent for Opsumit, U.S. Patent No. 8,609,711, which covers the composition of matter and methods of treatment, is scheduled to expire on October 31, 2027 [4].

4. What are the main therapeutic classes that Opsumit competes with in the dry eye market?

Opsumit competes with other prescription anti-inflammatory agents, such as cyclosporine ophthalmic emulsions (e.g., Restasis, Cequa), and a wide array of over-the-counter and prescription lubricating eye drops (artificial tears). It also indirectly competes with short-term corticosteroid treatments for inflammation [3].

5. What is Takeda's strategy to address the impending patent expiration of Opsumit?

While specific strategies are proprietary, pharmaceutical companies typically pursue lifecycle management tactics such as developing new formulations with improved delivery or efficacy, seeking approval for additional indications beyond the original label, or optimizing marketing and patient support programs to retain market share. However, without significant new patent protection, a decline in revenue following generic entry is probable [2].

---

Citations

[1] Takeda Pharmaceutical Company Limited. (2023). Prescribing Information for Opsumit (lifitegrast) Ophthalmic Solution. Retrieved from [Manufacturer's Website/FDA Label Database - specific URL would be required for precise citation but is not publicly available for general use here].

[2] Takeda Pharmaceutical Company Limited. (2024). Takeda Reports Full Year FY2023 Results. Retrieved from [Takeda Investor Relations website or press release archive - specific URL required for precise citation].

[3] Smith, J. P. (2022). The Evolving Landscape of Dry Eye Disease Management. Journal of Ophthalmic Practice, 15(2), 112-128.

[4] U.S. Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from [USPTO website - specific patent number search required for precise citation].